Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.59 |
| ▸ | CA2 | P00918 | 10/20 | 0.59 |
| ▸ | CA12 | O43570 | 5/20 | 0.59 |
| ▸ | CA9 | Q16790 | 5/20 | 0.59 |
| ▸ | CCNC | P24863 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822013 | 0.96 | CA1 (0.60) | CA1CA2CA12CA9CCNC | |
| SCHEMBL27138446 | 0.95 | CA1 (0.55) | CA1CA2CA12CA9CCNC | |
| SCHEMBL10191081 | 0.95 | CA1 (0.61) | CA1CA2CA12CA9CCNC | |
| SCHEMBL16930099 | 0.95 | CA1 (0.61) | CA1CA2CA12CA9CCNC | |
| SCHEMBL29040410 | 0.95 | CA1 (0.61) | CA1CA2CA12CA9CCNC | |
| SCHEMBL23835564 | 0.95 | CA1 (0.61) | CA1CA2CA12CA9CCNC | |
| SCHEMBL29040473 | 0.95 | CA1 (0.61) | CA1CA2CA12CA9CCNC | |
| SCHEMBL4640090 | 0.95 | CA1 (0.61) | CA1CA2CA12CA9CCNC | |
| SCHEMBL29040417 | 0.95 | CA1 (0.61) | CA1CA2CA12CA9CCNC | |
| SCHEMBL17162051 | 0.94 | CA1 (0.55) | CA1CA2CA12CA9CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260085058-A1 | DEGRADERS OF SON OF SEVENLESS HOMOLOG 1 | YUAN YU (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260014261-A1 | TARGETED PROTEIN MODIFICATION | WEATHERWAX BIOTECHNOLOGIES CORP (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4543439-A2 | NRF2 PROTEIN DEGRADERS | Ganymede Oncology, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | disclosed |
| WO-2024112611-A1 | TARGETED PROTEIN MODIFICATION | WEATHERWAX BIOTECHNOLOGIES CORPORATION (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-4368625-A1 | SHP2 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-05-15 | — | — | EP | disclosed |
| EP-0757049-B1 | Camptothecin derivatives | TANABE SEIYAKU CO (JP) | 1999-03-24 | — | — | EP | disclosed |
| US-5837673-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 1998-11-17 | — | — | US | disclosed |
| EP-0845464-A2 | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds as intermediates for camptothecin derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1998-06-03 | — | — | EP | disclosed |
| EP-0781781-A2 | Camptothecin derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1997-07-02 | — | — | EP | disclosed |
| EP-0757049-A1 | Camptothecin derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1997-02-05 | — | — | EP | disclosed |
| US-4983328-A | ANTITUMOR AGENTS | BRISTOL-MYERS COMPANY (US) | 1991-01-08 | — | — | US | disclosed |
| EP-0229944-A2 | Novel tetrahydroisoquinoline derivatives | SYNTEX (U.S.A.) INC. (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4518532-A | ANTITIMOR | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-05-21 | — | — | US | disclosed |
| US-4518802-A | IMMUNOSTIMULANT | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-05-21 | — | — | US | disclosed |
| US-4430346-A | N-(4-(3-AMINOPROPYL)AMINOBUTYL)-2-(CS)-7-GUANIDINO-3 -HYDROXYHEPTANAMIDE)-2-HYDROXYETHANAMIDE, ESTERS, AMIDATION ACID CATALYST | BRISTOL-MYERS COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN2 | CA1 3382/4885CA2 1424/4885CA12 3672/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | CA1 3382/4885CA2 1424/4885CA12 3672/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | CA1 2045/4885CA2 2413/4885CA12 3603/4885 |
| US-20260014261-A1 | TARGETED PROTEIN MODIFICATION | MDM2, TP53, VHL | CA1 3879/4885CA2 3600/4885CA12 3614/4885 |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | CA1 3789/4885CA2 2041/4885CA12 3947/4885 |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | CA1 4531/4885CA2 3954/4885CA12 4622/4885 |
| US-20260085058-A1 | DEGRADERS OF SON OF SEVENLESS HOMOLOG 1 | SOS1, KRAS, SOS2 | CA1 2798/4885CA2 2906/4885CA12 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.